AhR antagonists should be explored as a potential therapeutic strategy in diabetes due to their ability to reduce inflammation, improve insulin sensitivity, and mitigate obesity-associated metabolic dysfunction [131,247,248]. Here, AHR is linked to obesity due to melanocortin 4 receptor deficiency.